Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. 2007

Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
Department of Internal Medicine, Nagasaki Municipal Hospital, Nagasaki, Japan.

BACKGROUND Irinotecan and gemcitabine are effective against non-small cell lung cancer. We conducted a phase I study of the combined use of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer to determine dose-limiting toxicities and maximum tolerated dose. METHODS Patients were treated with irinotecan followed by gemcitabine on days 1 and 8 every 3 weeks. Gemcitabine dose was fixed at 1000 mg/m2, and irinotecan dose was increased from 60 mg/m2. RESULTS A total of 16 patients was enrolled. Maximum tolerated dose of irinotecan was determined up to level 3 (irinotecan 100 mg/m2). In Japan, the maximum approved weekly dose of irinotecan is 100 mg/m2, so this was the dose that was used. Only very mild hematological and non-hematological toxicities were noted. CONCLUSIONS Use of 100 mg/m2 irinotecan followed by 1000 mg/m2 gemcitabine on days 1 and 8 every 3 weeks warrants a phase II study.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077146 Irinotecan A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin,CPT 11,CPT-11,Camptosar,Camptothecin-11,Irinotecan Hydrochloride,Irrinotecan,NK012 Compound,SN 38,SN 38 11,SN-38,SN-38-11,7 Ethyl 10 hydroxycamptothecin,CPT11,Camptothecin 11,SN3811
D000093542 Gemcitabine A deoxycytidine antimetabolite used as an antineoplastic agent. 2',2'-Difluoro-2'-Deoxycytidine,2',2'-Difluorodeoxycytidine,2'-Deoxy-2',2''-Difluorocytidine-5'-O-Monophosphate,2'-Deoxy-2'-Difluorocytidine,Gemcitabine Hydrochloride,Gemcitabine, (D-threo-pentafuranosyl)-Isomer,Gemcitabine, (alpha-D-threo-pentofuranosyl)-Isomer,Gemcitabine, (beta-D-threo-pentafuranosyl)-Isomer,Gemicitabine,2',2'-DFDC,Gemzar,LY 188011,LY-188011,dFdCyd,188011, LY,2' Deoxy 2' Difluorocytidine,2' Deoxy 2',2'' Difluorocytidine 5' O Monophosphate,Hydrochloride, Gemcitabine

Related Publications

Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
May 2010, Clinical lung cancer,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
June 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
February 1999, British journal of cancer,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
January 2003, Anticancer research,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
January 2003, Lung cancer (Amsterdam, Netherlands),
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
January 1991, Cancer chemotherapy and pharmacology,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
February 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
January 2005, Anticancer research,
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
July 2004, Lung cancer (Amsterdam, Netherlands),
Hiroshi Takatani, and Hiroshi Soda, and Yoichi Nakamura, and Akitoshi Kinoshita, and Masaaki Fukuda, and Seiji Nagashima, and Minoru Fukuda, and Yoshifumi Soejima, and Hirofumi Nakano, and Mikio Oka, and Shigeru Kohno, and
October 2008, Lung cancer (Amsterdam, Netherlands),
Copied contents to your clipboard!